Pregrel® is developed by Seung-Jung Park.

What development phase is Pregrel® in?

Pregrel® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Pregrel®

Seung-Jung Park · FDA-approved active Small molecule Quality 0/100

Pregrel®, marketed by Seung-Jung Park, is a drug with an unspecified mechanism and primary indication, currently generating unknown revenue in its market segment. The key strength of Pregrel® is its market presence, supported by a key composition patent that expires in 2028. The primary risk is the lack of detailed clinical trial results and competitor information, which may impact its long-term market position.

At a glance

Generic name	Pregrel®
Also known as	clopidogrel
Sponsor	Seung-Jung Park
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effectiveness of Clopidogrel Resinate in PCI(PRIDE) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pregrel® CI brief — competitive landscape report
Pregrel® updates RSS · CI watch RSS
Seung-Jung Park portfolio CI